Jan 13, 2021 / 01:20PM GMT
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior Analyst
Good morning, everybody. I'm Chris Schott at JPMorgan. I'm very pleased to be hosting a fireside chat with Teva this morning. We have the Teva management team with us, and we're going to start with some opening comments from Teva's CEO, Kare Schultz, and we'll go into the Q&A.
So first of all, Kare and Eli, first, thanks for joining us, and happy new year to everybody.
Questions and Answers:
Christopher Thomas Schott - JPMorgan Chase & Co, Research Division - Senior AnalystI just was -- thinking back to, I think, Kare, this is your third year presenting at the JPMorgan conference as CEO of Teva. I was really thinking back, and you've made a lot of progress repositioning the company during that time. So as we turn to 2021, hopefully, a more normalized year for everybody, would love to just hear your thoughts in terms of how you see Teva positioned today and your key priorities for the organization as we think about the company going forward.
Trustpilot
